Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gamcemetinib - Bristol-Myers Squibb

Next Previous
X
Search
Drug Profile

Gamcemetinib - Bristol-Myers Squibb

Alternative Names: BMS-986371; CC-99677

Latest Information Update: 24 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Class Anti-inflammatories
  • Mechanism of Action MAP-kinase-activated kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Ankylosing spondylitis; Inflammation

Most Recent Events

  • 27 Mar 2024 Pharmacokinetics and adverse events data from a phase I trial (In volunteers) presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics 2024 (ASCPT-2024)
  • 26 Oct 2023 Discontinued - Phase-I for Inflammation (In volunteers) in USA, United Kingdom (PO) prior to October 2023 (Bristol-Myers Squibb pipeline, October 2023)
  • 26 Oct 2023 Discontinued - Phase-II for Ankylosing spondylitis in Turkey, Spain, Poland, Romania, Poland, Czech Republic, China, USA, Germany (PO) prior to October 2023 (Bristol-Myers Squibb pipeline, October 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top